Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is an interleukin‑12/23 inhibitor presented as a sterile solution for intravenous use. It is prescribed for adults with moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis when other systemic therapies are insufficient.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products, ensuring product integrity from manufacturing to delivery.

Imuldosa (ustekinumab) targets the interleukin‑12 and interleukin‑23 pathways, providing therapeutic benefit in several immune‑mediated inflammatory conditions. - Plaque psoriasis: reduces skin lesions and improves quality of life in moderate to severe cases. - Psoriatic arthritis: alleviates joint inflammation and slows disease progression. - Crohn's disease: induces remission and promotes mucosal healing in moderate to severe disease. - Ulcerative colitis: helps achieve clinical remission in patients with active disease.

Adverse reactions to Imuldosa may vary in frequency and severity.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as cough or sore throat. - Headache: transient and usually mild. - Injection site reactions: redness or swelling at the infusion site.

Serious or Rare Side Effects: - Serious infections: including tuberculosis or opportunistic infections. - Hypersensitivity reactions: anaphylaxis or severe allergic response. - Malignancies: potential increased risk of certain cancers.

Before initiating Imuldosa, clinicians should consider several precautionary measures to ensure patient safety. - Screen for latent tuberculosis: perform testing and treat if positive before therapy. - Evaluate for active infections: postpone treatment until infections are resolved. - Monitor for malignancy: conduct regular cancer screenings as per guidelines. - Assess vaccination status: administer necessary vaccines prior to starting therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use can cause severe infection; avoid during treatment. - Immunosuppressants: combined use may markedly increase infection risk.

Moderate Interactions (Monitor Closely): - Antifungal agents: may require monitoring for additive immunosuppression. - Cytochrome P450 substrates: although limited, observe for potential changes in drug levels. - Concomitant biologics: using multiple biologic agents can heighten adverse event risk.